- Home
- SLN vs PALI Comparison
SLN vs PALI Comparison
Compare SLN & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLN | PALI |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United Kingdom | United States |
| Employees | 116 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.2M | 240.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SLN | PALI |
|---|---|---|
| Price | $5.83 | $1.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $42.60 | $12.00 |
| AVG Volume (30 Days) | 345.9K | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $1.97 | $0.55 |
| 52 Week High | $7.91 | $2.64 |
Technical Indicators
Market Signals| Indicator | SLN | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 50.99 |
| Support Level | $5.79 | $1.58 |
| Resistance Level | $6.19 | $2.05 |
| Average True Range (ATR) | 0.58 | 0.17 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 37.66 | 60.29 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.